Research investigators
Despite advances in healthcare, there are still many diseases that have no cure or for which new treatments and vaccines are needed to prevent transmission or help patients better control their symptoms. Therefore, working with healthcare professionals to conduct research is vital to GSK’s mission of helping people do more, feel better and live longer.
At the same time, GSK remains firmly committed to its core value of transparency and as such is disclosing research payments made during 2010 for research studies led by U.S. healthcare professionals that began on or after 1 January 2010. The information on this page pertains to all phases of medicine and product discovery and development, including nonclinical research studies and Phase I-IV clinical trials. This report will be updated annually.
At a later date, this disclosure will be extended to research payments made to institutions and associated healthcare professionals outside of the U.S for the conduct of research. For more information regarding GSK’s approach to research and research disclosure, please see the Research Practices section of GSK’s Corporate Responsibility Report.
Background
To help you understand the information we are disclosing, the payments listed here were provided to:
- U.S. research entities and institutions associated with principal investigators (“PI”) or lead researchers when the principal investigator (for more information on the role of the principal investigator see http://www.gsk-clinicalstudyregister.com/glossary2.jsp) or lead researcher is a U.S. healthcare professional, and/or to
- U.S Healthcare Professionals who provide services to GSK when they are a PI or lead researcher in a GSK sponsored or supported study.
In most cases GSK does not know the amount of compensation the PI or lead researcher receives from his or her institution. This report includes payments made directly by GSK or indirectly through a third party such as a Contract Research Organisation (“CRO”).
For purposes of research payments, GSK defines a U.S. Healthcare professional as an individual who can prescribe or dispense a prescription medicine to a U.S. patient. In order to be eligible to conduct GSK research, a U.S. Healthcare professional also must be qualified to undertake and be responsible for the research study.
Payments for research do not just constitute compensation for the PI or lead researcher. Research costs also include payments for any study visits and any other costs to conduct the research study at the site, such as:
- Procedures (diagnostic tests, laboratory services and patient assessments)
- Detailed monitoring of clinical outcomes and drug safety, and
- Institutional overhead.
Finally, GSK is committed to providing as complete and accurate a disclosure as possible. However, despite our best efforts, from time to time errors can occur (e.g. when a PI or lead researcher moves to a different institution). As a result, we have established internal processes to continually review and validate our disclosures and to correct the records when errors are identified.
Using the Report
The disclosure report contains a number of different attributes or fields. These are study number, payee, PI or lead researcher, city, state and amount.
- The study identification number reflects GSK’s internal number which we use for tracking purposes. This identification number is also used for the clinical studies that are made publicly available on clinical study registers such as GSK’s Clinical Study Register and ClinicalTrials.gov
- Payee refers to the institution, entity or individual initially receiving the payment (e.g. to whom the check is made out)
- The city/state fields correspond to the location of the PI or lead researcher and not necessarily to the payee.
- Payment amounts are recorded in U.S. dollars.
In the case of large, multi-center clinical trials, it is not unusual for a single study number to be associated with a number of different payees (also called investigational sites), or for large payees (e.g. large academic medical centers) to be involved with a number of different GSK research studies.
For questions or comments regarding this disclosure, please contact the GSK Response Center at 1-888-825-5249 during the hours of
8 a.m.-6 p.m. Eastern Time Monday through Friday.
Research payments
